These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29572333)

  • 1. Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.
    Yu J; Zhou Z; Tay-Sontheimer J; Levy RH; Ragueneau-Majlessi I
    Drug Metab Dispos; 2018 Jun; 46(6):835-845. PubMed ID: 29572333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.
    Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I
    Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
    Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
    Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.
    Yu J; Zhou Z; Owens KH; Ritchie TK; Ragueneau-Majlessi I
    Drug Metab Dispos; 2017 Jan; 45(1):86-108. PubMed ID: 27821435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
    Shebley M; Liu J; Kavetskaia O; Sydor J; de Morais SM; Fischer V; Nijsen MJMA; Bow DAJ
    Drug Metab Dispos; 2017 Jul; 45(7):755-764. PubMed ID: 28483778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications.
    Yu J; Wang Y; Ragueneau-Majlessi I
    Clin Ther; 2022 Nov; 44(11):1536-1544. PubMed ID: 36210218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review.
    Yu J; Ritchie TK; Mulgaonkar A; Ragueneau-Majlessi I
    Drug Metab Dispos; 2014 Dec; 42(12):1991-2001. PubMed ID: 25271211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
    Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
    Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Enzyme- and Transporter-mediated Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2022: A Detailed Analysis of In Vitro and Clinical Data Available in New Drug Application Reviews.
    Yu J; Wang Y; Ragueneau-Majlessi I
    Clin Ther; 2024 Jun; 46(6):499-508. PubMed ID: 38734524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations.
    Yu J; Wang Y; Ragueneau-Majlessi I
    Drug Metab Dispos; 2022 Jan; 50(1):1-7. PubMed ID: 34620694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.
    Bolleddula J; Ke A; Yang H; Prakash C
    CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):577-588. PubMed ID: 33822485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment.
    Polasek TM; Lin FP; Miners JO; Doogue MP
    Br J Clin Pharmacol; 2011 May; 71(5):727-36. PubMed ID: 21223357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir.
    Ouwerkerk-Mahadevan S; Snoeys J; Peeters M; Beumont-Mauviel M; Simion A
    Clin Pharmacokinet; 2016 Feb; 55(2):197-208. PubMed ID: 26353895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
    Yamazaki S; Loi CM; Kimoto E; Costales C; Varma MV
    Drug Metab Dispos; 2018 Aug; 46(8):1200-1211. PubMed ID: 29739809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters.
    Ramsden D; Wu JT; Zerler B; Iqbal S; Jiang J; Clausen V; Aluri K; Gu Y; Dennin S; Kim J; Chong S
    Drug Metab Dispos; 2019 Oct; 47(10):1183-1194. PubMed ID: 31270142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome-P450-Mediated Drug
    Steyn SJ; Varma MVS
    Mol Pharm; 2020 Aug; 17(8):3024-3032. PubMed ID: 32589434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.
    Kasserra C; Assaf M; Hoffmann M; Li Y; Liu L; Wang X; Kumar G; Palmisano M
    J Clin Pharmacol; 2015 Feb; 55(2):168-78. PubMed ID: 25159194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.
    Kosa RE; Lazzaro S; Bi YA; Tierney B; Gates D; Modi S; Costales C; Rodrigues AD; Tremaine LM; Varma MV
    Drug Metab Dispos; 2018 Aug; 46(8):1179-1189. PubMed ID: 29880631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.
    Elmeliegy M; Vourvahis M; Guo C; Wang DD
    Clin Pharmacokinet; 2020 Jun; 59(6):699-714. PubMed ID: 32052379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.